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ABSTRACT MATERIALS AND METHODS 
Two isolates of Candida dubliniensis were identified from a 
collection of 30 examined from Israel in a molecular epidemi- 
ology study. The 30 isolates were tentatively identified as Can- 
dida albicans. The new species, C. dubliniensis, is being 
reported from new geographic locales. These two isolates, 
from an Arab and a Druze patient, are the first to be reported 
from the Middle East. 
Int J Infect Dis 2001; 5:40-42. 
Candida dubliniensis is a recently described species of 
Candida.’ This organism shows homology for much of 
its genome with Candida albicans, and the two species 
are indistinguishable in many biochemical reactions and 
morphologic tests. It is likely C. dubliniensis has been 
misidentified as C. albicans in the past. Although C. 
dubliniensis was initially associated with oropharyngeal 
disease and carriage in human immunodeficiency virus 
(HIV)-infected persons, reports of other types of infec- 
tions in other immunocompromised and in noncompro- 
mised individuals are appearing. Isolates have been 
reported from several areas of the world, but none have 
been reported from the Middle East. A geographic mole- 
cular epidemiologic survey of C. albicans isolates, includ- 
ing those from Israel, enabled researchers to identify the 
first C. dubziniensis reported from the Middle East.2 This 
report demonstrates the global range of C. dubliniensis, 
and shows this newly described organism is not geo- 
graphically restricted, as was initially considered. 
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Thirty Israeli C. albicans isolates were tentatively identi- 
fied by the ability to produce chlamydospores on tauro- 
cholate agar medium, growth on Bacto Mycobiotic agar 
(D&o, Detroit, MI), and via the automated biochemical 
identification system ID 32C (bioMerieux, Marcy l’Etoile, 
France). Isolates of C. albicans from other regions were 
identified as previously described.3 Seven authentic iso- 
lates of C. dubliniensis, including the ex-type strain, were 
kindly provided by Derek Sullivan, Dublin, Ireland, and 
Frank Odds, Aberdeen, Scotland, identified by atypical 
green color on CHROMagar Candida (CHROMagar Micro- 
biology, Paris), demonstration of absence of intracellular 
betaglucosidase activity, and weak hybridization with the 
C. albicans-specific oligonucleotide sequence Ca 3.” 
Cellular DNA was isolated and digested with EcoRI 
endonuclease,5 and the resultant fragments were electro- 
phoresed in agar, stained, and photographed, as previ- 
ously described.’ 
Primers used for the polymerase chain reaction (PCR) 
designed for three separate areas of DNA encoding the 
ribosomal RNA differentiate C. albicuns from C. dublin- 
iensis, as previously described.’ Polymerase chain reac- 
tions, endonuclease digestion of the amplicons, and 
electrophoretic analysis of the digests, were performed as 
previously described.” 
RESULTS 
On restriction fragment length polymorphism (RFLP), 
two throat isolates, from an 1 l-year-old Arab male and a 
20-year-old Druse male, lacked both the 3.7 and 4.2 kb 
bands used to divide C. aZbicans into genotypic groups,” 
as did seven authentic C. dubliniensis repository isolates 
(including the ex-type strain) (Figure 1). All three PCR 
methods also showed identity of these nine isolates. Fig- 
ure 2 depicts the results after amplification of the 25s 
rDNA, using primers spanning the intron.’ Similar results 
were obtained after digestion with DdeI of the intergenic 
transcribed spacer (ITS) amplicon and digestion with 
HaeIII of the V3 region of the 25s rDNA amplicon (data 
not shown).” 
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Figure 1. Representative photograph of an ultraviolet transilluminated 
ethidium bromide-stained agarose gel. Gel shows RFLP patterns of 
C. albicans and C. dubliniensis after digestion of cellular DNA with 
EcoRl. Lane 1, C. albicans genotype B; lanes 2 to 4, C. albicans 
genotype C; lanes 5 and 6, C. dubliniensis isolates from Israel; lane 7, 
C. albicans genotype C; lane 8, C. albicans genotype B; lanes 9 to 12, 
C. albicans genotype A. Lane M provides size markers of 23.1, 9.4, 
6.5, 4.3, 2.3, and 2.0 kb, given in descending order. 
Twenty-eight other Israeli isolates were C. albicans 
by these RFLP and PCR methods, as were 430 non-Israeli 
isolates from various regions of the world concurrently 
studied. Patterns from representative C. albicans isolates 
are also shown in Figures 1 and 2. 
The Arab boy had a clinical diagnosis of peritonsilli- 
tis, dysphagia, and fever. The Druse man was hospitalized 
because of anemia, fever, and pharyngitis. Neither patient 
had any risk factors for acquired immunodeficiency syn- 
drome (AIDS). Follow-up study of these two individuals 
is in progress. Serologic workup of the boy revealed HIV 
seronegativity. Of the 30 Candida isolates, the isolate 
from the Arab patient was 1 of 11 obtained from Arab 
patients for the study, and the isolate from the Druse 
patient was 1 of 3 obtained from Druse patients. In con- 
trast, none of the I6 isolates obtained from Jewish 
patients were C. dubliniensis. 
Figure 2. Representative photograph of ethidium bromide-stained 
agarose gel separating the amplicons obtained after PCR with primers 
spanning the intron position of the 25s rDNA. Panel A: Lanes 1 to 4 
and 11, C. albicans genotype B; lanes 5 to 7, IO and 15, C. albicans 
genotype C; lane 8, no product; lane 9, C. dubliniensis isolate from 
Israel; lanes 12 to 14 and 16, C. albicans genotype A. Panel 5: Lanes 
1 to 3, 6 and 7, and 9 to 11, C. albicans genotype A; lanes 4 and 8, 
C. albicans genotype C; lane 5, C. albicans genotype B; lanes 12 to 
14, putative Candida stellafoidea (identical to C. albicans genotype 
B)‘? lane 15, an authentic C. dubliniensis, CM2 (CBS 7988) for com- 
parison with lane 9 in Panel A. Lane M provides size markers in 
descending order of 2176, 1766, 1230, 1033, 653, 517, 453, 394, 298, 
234, and 154 base pairs. 
DISCUSSION 
The two patient isolates were demonstrated to be indis- 
tinguishable from C. dubliniensis, and distinct from C. 
albicuns, by RFLP and three PCR-based methods. These 
identification methods are rapid, specific, and repro- 
ducible” and superior to methods that rely on variable 
phenotypic characteristics, although some tests’ and, 
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particularly, combinations of them8 increase the reliability 
and are more readily available to the clinical laboratory. 
The frequency of C. dubliniensis in the small sample 
of isolates from Israel is greater than general estimates of 
the relative prevalence of this organism.‘,s This is par- 
ticularly the case for the Arab and Druse subsets of the 
sample, but larger epidemiologic surveys of Candida 
from Israel and other Middle Eastern countries are 
required to assess the relative frequency in this region, 
and the ethnic distribution of this organism. Such a study 
is presently in progress in Israel. Examination of another 
50 putative C. albicans isolates has tentatively identified 
two additional isolates of C, dubliniensis. 
ADDENDUM 
Following preliminary presentation and submission of 
this research,* another report has appeared confirming 
the presence of C. dubliniensis in Israel9 
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